Do inpatient antimicrobial stewardship programs help us in the battle against antimicrobial resistance?
We propose to conduct a comprehensive analysis of the impact of ASPs on relevant clinical outcomes in a large integrated health care system. Specifically, we will evaluate the changes in consumption of targeted ASP drugs pre- and post-ASP and the changes in inpatient infection rates with clinically important drug-resistant organisms (DROs) pre- and post-ASP.
Principal Investigator:Sara Yee Tartof, PhD, MPH
Funding Source:National Institutes of Health (NIH)
Funding Years:2017 - 2019
Identification of risk factors for resistant Pseudomonas aeruginosa infections with or without ESBL among hospitalized patients and developments and validation of a risk predictive tool
This study aims to develop a clinical risk prediction tool for antibiotic resistant Pseudomonas infections among inpatients.